{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:15:32Z","timestamp":1791231332773,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004166","name":"Warszawski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["MB\/M\/09 (16)"],"award-info":[{"award-number":["MB\/M\/09 (16)"]}],"id":[{"id":"10.13039\/501100004166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Progressive Supranuclear Palsy (PSP) is an atypical parkinsonism. Major subtypes of the disease: PSP-Richardson\u2019s Syndrome (PSP-RS) and PSP Parkinsonism Predominant (PSP-P) vary in clinical features, the pathomechanism remains unexplored. The aim of this work is to analyze the relevance of glial cell line-derived neurotrophic factor (GDNF) evaluation in the serum and cerebrospinal fluid (CSF) in PSP subtypes and to verify its significance as a possible factor in the in vivo examination. Authors assessed the concentration of GDNF in the serum and CSF of 12 patients with PSP-RS, 12 with PSP-P and 12 controls. Additionally authors evaluated patients using Unified Parkinson\u2019s Disease Rating Scale\u2014III part (UPDRS-III), Frontal Assessment Battery (FAB) and Magnetic Resonance Imaging (MRI). The evaluation revealed significantly increased concentrations of GDNF in the CSF among PSP-RS patients and substantially increased concentrations of GDNF in the serum in PSP-P. Though the GDNF concentrations differentiated PSP subtypes, no correlations between with clinical factors were observed however certain correlations with atrophic changes in MRI were detected. GDNF is a factor which may impact the pathogenesis of PSP. Possible implementation of GDNF as a therapeutic factor could be a perspective in the search for therapy in this currently incurable disease.<\/jats:p>","DOI":"10.1038\/s41598-024-53355-y","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T16:02:18Z","timestamp":1706889738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The significance of glial cell line-derived neurotrophic factor analysis in Progressive Supranuclear Palsy"],"prefix":"10.1038","volume":"14","author":[{"given":"Piotr","family":"Alster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmara","family":"Otto-\u015alusarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanis\u0142aw","family":"Szlufik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Duszy\u0144ska-W\u0105s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Drzewi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Wierci\u0144ska-Drapa\u0142o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Struga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Kuty\u0142owski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Madetko-Alster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"issue":"6","key":"53355_CR1","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger, G. U. et al. Clinical diagnosis of Progressive Supranuclear Palsy: The movement disorder society criteria. Mov. Disord. 32(6), 853\u2013864. https:\/\/doi.org\/10.1002\/mds.26987 (2017).","journal-title":"Mov. Disord."},{"key":"53355_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fneur.2020.00180","volume":"11","author":"P Alster","year":"2020","unstructured":"Alster, P., Madetko, N., Koziorowski, D. & Friedman, A. Progressive Supranuclear Palsy-parkinsonism predominant (PSP-P)-A clinical challenge at the boundaries of PSP and parkinson\u2019s disease (PD). Front. Neurol. 11, 180. https:\/\/doi.org\/10.3389\/fneur.2020.00180 (2020).","journal-title":"Front. Neurol."},{"issue":"10","key":"53355_CR3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/jnnp-2017-315857","volume":"88","author":"E Jabbari","year":"2017","unstructured":"Jabbari, E., Zetterberg, H. & Morris, H. R. Tracking and predicting disease progression in Progressive Supranuclear Palsy: CSF and blood biomarkers. J. Neurol. Neurosurg. 88(10), 883\u2013888. https:\/\/doi.org\/10.1136\/jnnp-2017-315857 (2017).","journal-title":"J. Neurol. Neurosurg."},{"issue":"4","key":"53355_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/WCO.0b013e32833be924","volume":"23","author":"DW Dickson","year":"2010","unstructured":"Dickson, D. W., Ahmed, Z., Algom, A. A., Tsuboi, Y. & Josephs, K. A. Neuropathology of variants of Progressive Supranuclear Palsy. Curr. Opin. Neurol. 23(4), 394\u2013400. https:\/\/doi.org\/10.1097\/WCO.0b013e32833be924 (2010).","journal-title":"Curr. Opin. Neurol."},{"issue":"2\u20133","key":"53355_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/s0165-0173(00)00030-8","volume":"33","author":"GJ Siegel","year":"2000","unstructured":"Siegel, G. J. & Chauhan, N. B. Neurotrophic factors in Alzheimer\u2019s and Parkinson\u2019s disease brain. Brain Res. Brain Res. Rev. 33(2\u20133), 199\u2013227. https:\/\/doi.org\/10.1016\/s0165-0173(00)00030-8 (2000).","journal-title":"Brain Res. Brain Res. Rev."},{"issue":"7","key":"53355_CR6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/mds.10473","volume":"18","author":"Movement Disorder Society Task Force on Rating Scales for Parkinson\u2019s Disease","year":"2003","unstructured":"Movement Disorder Society Task Force on Rating Scales for Parkinson\u2019s Disease. The Unified Parkinson\u2019s Disease Rating Scale (UPDRS): Status and recommendations. Mov. Disord. 18(7), 738\u2013750. https:\/\/doi.org\/10.1002\/mds.10473 (2003).","journal-title":"Mov. Disord."},{"key":"53355_CR7","doi-asserted-by":"publisher","first-page":"630153","DOI":"10.3389\/fneur.2021.630153","volume":"12","author":"P Alster","year":"2021","unstructured":"Alster, P. et al. The role of frontal assessment battery and frontal lobe single-photon emission computed tomography in the differential diagnosis of Progressive Supranuclear Palsy variants and corticobasal syndrome-a pilot study. Front. Neurol. 12, 630153. https:\/\/doi.org\/10.3389\/fneur.2021.630153 (2021).","journal-title":"Front. Neurol."},{"issue":"11","key":"53355_CR8","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1212\/WNL.55.11.1621","volume":"55","author":"B Dubois","year":"2000","unstructured":"Dubois, B., Slachevsky, A., Litvan, I. & Pillon, B. F. A. B. The FAB: A frontal assessment battery at bedside. Neurology 55(11), 1621\u20131626 (2000).","journal-title":"Neurology"},{"key":"53355_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1080\/13554790590962933","volume":"4","author":"DC Paviour","year":"2005","unstructured":"Paviour, D. C. et al. Can the frontal assessment battery (FAB) differentiate bradykinetic rigid syndromes? Relation of the FAB to formal neuropsychological testing. Neurocase 4, 274\u2013282. https:\/\/doi.org\/10.1080\/13554790590962933 (2005).","journal-title":"Neurocase"},{"issue":"2","key":"53355_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/gps.4751","volume":"33","author":"M Hurtado-Pomares","year":"2018","unstructured":"Hurtado-Pomares, M. et al. The frontal assessment battery in clinical practice: A systematic review. Int. J. Geriatr. Psychiatry 33(2), 237\u2013251 (2018).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"53355_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1148\/radiol.2453061703","volume":"246","author":"A Quattrone","year":"2008","unstructured":"Quattrone, A. et al. MR imaging index for differentiation of Progressive Supranuclear Palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 246, 214\u2013221. https:\/\/doi.org\/10.1148\/radiol.2453061703 (2008).","journal-title":"Radiology"},{"key":"53355_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.parkreldis.2018.07.016","volume":"54","author":"A Quattrone","year":"2018","unstructured":"Quattrone, A. et al. A new MR imaging index for differentiation of Progressive Supranuclear Palsy-parkinsonism from Parkinson\u2019s disease. Parkinson. Relat. Disord. 54, 3\u20138. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.07.016 (2018) (Epub 2018 Jul 25).","journal-title":"Parkinson. Relat. Disord."},{"key":"53355_CR13","doi-asserted-by":"publisher","first-page":"1136499","DOI":"10.3389\/fnins.2023.1136499","volume":"17","author":"SY Tong","year":"2023","unstructured":"Tong, S. Y. et al. Serum glial cell line-derived neurotrophic factor (GDNF) a potential biomarker of executive function in Parkinson\u2019s disease. Front Neurosci. 17, 1136499. https:\/\/doi.org\/10.3389\/fnins.2023.1136499 (2023).","journal-title":"Front Neurosci."},{"issue":"1","key":"53355_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00702-012-0876-x","volume":"120","author":"W Maruyama","year":"2013","unstructured":"Maruyama, W. & Naoi, M. \u201c70th Birthday Professor Riederer\u201d induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: A way to a disease-modifying therapy?. J. Neural Transm. (Vienna) 120(1), 83\u201389. https:\/\/doi.org\/10.1007\/s00702-012-0876-x (2013).","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"2","key":"53355_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/brainsci13020200","volume":"13","author":"L Wang","year":"2023","unstructured":"Wang, L., Gao, Z., Chen, G., Geng, D. & Gao, D. Low levels of adenosine and GDNF are potential risk factors for Parkinson\u2019s disease with sleep disorders. Brain Sci. 13(2), 200. https:\/\/doi.org\/10.3390\/brainsci13020200 (2023).","journal-title":"Brain Sci."},{"issue":"3","key":"53355_CR16","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3390\/life13030647","volume":"13","author":"T Numakawa","year":"2023","unstructured":"Numakawa, T. & Kajihara, R. Neurotrophins and other growth factors in the pathogenesis of Alzheimer\u2019s disease. Life Basel 13(3), 647. https:\/\/doi.org\/10.3390\/life13030647 (2023).","journal-title":"Life Basel"},{"issue":"2","key":"53355_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3233\/JAD-2009-1146","volume":"18","author":"G Straten","year":"2009","unstructured":"Straten, G., Eschweiler, G. W., Maetzler, W., Laske, C. & Leyhe, T. Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer\u2019s disease and normal controls. J. Alzheim. Dis. 18(2), 331\u2013337. https:\/\/doi.org\/10.3233\/JAD-2009-1146 (2009).","journal-title":"J. Alzheim. Dis."},{"key":"53355_CR18","doi-asserted-by":"publisher","first-page":"714186","DOI":"10.3389\/fnagi.2021.714186","volume":"13","author":"S Mitra","year":"2021","unstructured":"Mitra, S. et al. Increased endogenous GDNF in mice protects against age-related decline in neuronal cholinergic markers. Front Aging Neurosci. 13, 714186. https:\/\/doi.org\/10.3389\/fnagi.2021.714186 (2021).","journal-title":"Front Aging Neurosci."},{"issue":"7","key":"53355_CR19","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1007\/s10072-020-04909-1","volume":"42","author":"M Sharif","year":"2021","unstructured":"Sharif, M., Noroozian, M. & Hashemian, F. Do serum GDNF levels correlate with severity of Alzheimer\u2019s disease?. Neurol. Sci. 42(7), 2865\u20132872. https:\/\/doi.org\/10.1007\/s10072-020-04909-1 (2021) (Epub 2020 Nov 19).","journal-title":"Neurol. Sci."},{"issue":"39","key":"53355_CR20","doi-asserted-by":"publisher","first-page":"13127","DOI":"10.1523\/JNEUROSCI.2582-13.2014","volume":"34","author":"Y Konishi","year":"2014","unstructured":"Konishi, Y. et al. Deficiency of GDNF receptor GFR\u03b11 in Alzheimer\u2019s neurons results in neuronal death. J. Neurosci. 34(39), 13127\u201313138. https:\/\/doi.org\/10.1523\/JNEUROSCI.2582-13.2014 (2014).","journal-title":"J. Neurosci."},{"issue":"4","key":"53355_CR21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.4103\/1673-5374.205084","volume":"12","author":"TB Sampaio","year":"2017","unstructured":"Sampaio, T. B., Savall, A. S., Gutierrez, M. E. Z. & Pinton, S. Neurotrophic factors in Alzheimer\u2019s and Parkinson\u2019s diseases: Implications for pathogenesis and therapy. Neural Regen. Res. 12(4), 549\u2013557. https:\/\/doi.org\/10.4103\/1673-5374.205084 (2017).","journal-title":"Neural Regen. Res."},{"issue":"3","key":"53355_CR22","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3233\/JPD-202004","volume":"10","author":"RA Barker","year":"2020","unstructured":"Barker, R. A. et al. GDNF and Parkinson\u2019s disease: Where next? A summary from a recent workshop. J. Parkinson. Dis. 10(3), 875\u2013891. https:\/\/doi.org\/10.3233\/JPD-202004 (2020).","journal-title":"J. Parkinson. Dis."},{"issue":"1","key":"53355_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/1567205010666131120100743","volume":"11","author":"K Sopova","year":"2014","unstructured":"Sopova, K., Gatsiou, K., Stellos, K. & Laske, C. Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer\u2019s disease: From pathophysiology to novel treatment strategies. Curr. Alzheim. Res. 11(1), 27\u201339. https:\/\/doi.org\/10.2174\/1567205010666131120100743 (2014).","journal-title":"Curr. Alzheim. Res."},{"issue":"2","key":"53355_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pharmthera.2013.01.004","volume":"138","author":"SJ Allen","year":"2013","unstructured":"Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U. & Patel, N. K. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol. Ther. 138(2), 155\u2013175. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.01.004 (2013).","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"53355_CR25","doi-asserted-by":"publisher","first-page":"098","DOI":"10.1093\/braincomms\/fcac098","volume":"4","author":"WJ Scotton","year":"2022","unstructured":"Scotton, W. J. et al. A data-driven model of brain volume changes in Progressive Supranuclear Palsy. Brain Commun. 4(3), 098. https:\/\/doi.org\/10.1093\/braincomms\/fcac098 (2022).","journal-title":"Brain Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-53355-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-53355-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-53355-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T16:07:22Z","timestamp":1706890042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-53355-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["53355"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-53355-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]},"assertion":[{"value":"26 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2805"}}